Ramiro Ribeiro
Known title: Chief Medical OfficerCIK: 0002013623
Associated companies
Transaction History
| EYPT | ▲ Buy | Option Exercise | 2,437 | $20K | 6/30/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 2,438 | $20K | 6/30/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,437 | $37K | 6/30/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,438 | $37K | 6/30/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 2,437 | $20K | 4/17/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,437 | $37K | 4/17/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 2,438 | $20K | 3/4/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,438 | $44K | 3/4/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 2,437 | $20K | 2/17/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,437 | $37K | 2/17/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 29,250 | $242K | 1/5/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 42,544 | $727K | 1/5/2026 | View on chart |
| EYPT | ▲ Buy | Option Exercise | 19,667 | $0 | 1/3/2026 | View on chart |
| EYPT | ▼ Sell | Tax Withholding | 6,373 | $111K | 1/3/2026 | View on chart |
| EYPT | ▼ Sell | Open Market | 2,722 | $32K | 11/11/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Yahoo article highlights EYPT as a potential portfolio addition
A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.
Yahoo article highlights EYPT as a potential portfolio addition. A recent Yahoo article discussed EyePoint Inc. (EYPT) and listed reasons why the stock could be considered for a portfolio. The piece referenced the company's analyst consensus target of $25.91 and its 52‑week range of $2.93 to $19.11. The article’s positive tone adds to current market conversation around the stock.